About Jiangsu Trautec Medical Technology
Jiangsu Trautec Medical Technology, based in Changzhou’s biotech innovation district, leads China’s synthetic recombinant human collagen industry. Founded in 2015, the company operates:
- Large-scale SRHC production facilities
- Advanced R&D labs with $17M investment
- Medical and cosmetic applications development
- Biomaterials research centers
Following a $27M Series B investment in 2023, Trautec continues expanding its recombinant collagen technology across the Asia-Pacific region.
Frequently asked questions
Jiangsu Trautec Medical Technology operates in these areas:
- Recombinant Collagen Production
- Synthetic recombinant human collagen (SRHC)
- Biomaterial development
- Large-scale manufacturing
- Applications
- Medical solutions
- Cosmetic ingredients
- Biotechnology products
- Research Activities
- Protein development
- Nucleic acid research
- Biomaterial innovation
The company demonstrates these operational metrics:
| Category | Details |
|---|---|
| Financial Investment |
|
| Technical Capacity |
|
| Market Position |
|
The company operates from its main facility in China:
Manufacturing and R&D Center28 Shuanglong Road
Jintan Economic Development Zone
Changzhou City
Jiangsu Province
China
The facility includes:
- Production Areas
- SRHC manufacturing units
- Quality control laboratories
- Storage facilities
- Research Center
- R&D laboratories
- Testing facilities
- Development spaces
More details about Jiangsu Trautec Medical Technology
A leading biotechnology company in Changzhou
Jiangsu Trautec Medical Technology Co., Ltd., founded in 2015, operates as a cosmetic lab and medical technology company in Changzhou, China. The company specializes in the development of recombinant collagen for both medical and cosmetic applications.
Advanced research and development facilities
Located in the Jintan Economic Development Zone, the company has invested over $17 million in research facilities dedicated to synthetic recombinant human collagen (SRHC) production. Their state-of-the-art laboratory complex houses equipment for biomaterial development and testing.
Product development and services
- Recombinant collagen-based biomaterials
- Innovative proteins development
- Nucleic acids production
- Medical and cosmetic applications research
Market position and recent growth
As a market leader in China’s SRHC industry, Trautec has achieved large-scale production capabilities. Their recent $27 million Series B investment in 2023 demonstrates market confidence in their technology and growth potential.
Strategic location in Jiangsu Province
The company’s location in Changzhou City, situated in Jiangsu Province, positions it within China’s biotechnology corridor. This placement provides access to research institutions and a skilled workforce in the region’s expanding biotech sector.
Manufacturing capabilities
The Jintan Economic Development Zone facility enables Trautec to maintain full control over their production chain, from research and development to final product manufacturing, ensuring quality standards across all processes.
Company gallery
